Study Demonstrates GlySure System's Ability to Accurately Measure Blood Glucose Levels in the ICU
For the study, Use of an intravascular continuous blood glucose sensor during post operative ICU care of cardiac surgery patients, researchers used the GlySure CBGM system to measure blood glucose concentrations in 24 post cardiac surgery ICU patients continuously and in real-time. Blood samples were taken at regular intervals and the glucose concentrations measured. At the time of sampling, the GlySure monitor was time stamped to allow subsequent statistical analysis between the continuous GlySure sensor and the intermittent glucose values.
The researchers found glucose concentrations measured by the GlySure system correlated with the concentrations measured in the blood draws. They concluded the system can dramatically reduce the need for frequent intermittent sampling and offers the potential for early identification of hypoglycemic and hyperglycaemic excursions.
"'We are excited by these results," said Principal Investigator Dr. Krishna Prasad. "A device like this would be extremely valuable in managing these kinds of patients in the ICU. The system is also easy to set up and use, which are key requirements in critical care."
GlySure recently commenced a multi-center CE Trial on cardiac surgery patients, which the company expects to complete this fall.
Source: GlySure via PR Newswire
Published on : Wed, 25 Sep 2013
Print as PDF
Medos customized tubing sets have been individually designed, so that all customer requirements, depending on application and need can be realized. Furthermore tubing sets can be refined by rheoparin or x.eed coating.
NovaPort cannulas are designed specially to meet the needs of extracorporeal lung and heart support circuits and perioperative perfusion in minimally invasive heart surgery.All blood-contact surfaces of the NovaPort cannulas are coated with the bio- and...
The technical and clinical reference standard for all B·R·A·H·M·S PCT assays. All clinical cut-offs and algorithms were developed based on B·R·A·H·M·S PCT sensitive KRYPTOR. Homogeneous immunoassay for the quantitative d
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...